PEOPLE - BioControl Medical (Israel) makes appointments:
This article was originally published in Clinica
Executive Summary
BioControl Medical (Yehud, Israel), developer of advanced implantable devices for the treatment of autonomic diseases, has appointed Paul Hauptman as medical director. Dr Hauptman is professor of internal medicine at Saint Louis University School of Medicine and director of heart failure in the division of cardiology. The firm has appointed a distinguished board of scientific advisors. William Little (Professor of medicine and chief of the cardiology section, Wake Forest University Baptist Medical Center); Brian Olshansky (Professor of medicine and former director of clinical cardiac electrophysiology, University of Iowa Hospitals); Milton Packer (Professor and chair of the department of clinical sciences, University of Texas Southwestern Medical School); Hani Sabbah (Professor of medicine, Case Western Reserve University); Peter Schwartz (Chairman of cardiology, University of Pavia); and Karl Swedberg (Professor of medicine/head of department of emergency and cardiovascular medicine, Sahlgrenska Academy, Goteborg University).
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.